Despite promising efforts on tumour mutational burden, PD-L1 expression is still the only clinically available biomarker.7,8 Nonetheless, the value of tumour PD-L1 expression as a predictive biomarker is not straightforward. The gene discussed is CD274; the disease is neoplasm.